文献速递青光眼

MGV354治疗高眼压或青光眼的随机对照I/II期研究

A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.
PubMed 文献 · Am J Ophthalmol · 2018-05-24

该双盲随机赋形剂对照研究评估局部用可溶性鸟苷酸环化酶激活剂MGV354治疗高眼压或青光眼的安全性及降眼压疗效。第3部分中,MGV354 0.1%组第8天日间平均眼压较基线变化-0.6 mmHg,赋形剂组-1.1 mmHg,置信区间-0.7至1.7,主要结局指标未显示统计学显著差异。最常见不良事件为结膜充血和眼充血。

要点

  • MGV354 0.1%降眼压效果与赋形剂相比无统计学显著差异。
  • 第3部分第8天日间平均眼压变化:MGV354组-0.6 mmHg,赋形剂组-1.1 mmHg。
  • 最常见不良事件为结膜充血和眼充血,与药理学作用一致。

核心结论

  • MGV354 0.1%基于主要结局指标在降眼压方面与赋形剂相比无统计学显著效果。
  • MGV354产生与药理学作用一致的眼充血。

研究设计与样本

  • 双盲、随机、赋形剂对照研究,分3部分。
  • 第1部分在32名健康志愿者中评估安全性和耐受性以确定最大耐受剂量。
  • 第2部分在16名高眼压或青光眼患者中评估安全性和耐受性。
  • 第3部分为多中心试验,在50名上午8时眼压至少24 mmHg的患者中评估最大耐受剂量每晚给药1周的降眼压疗效。
  • 主要结局指标为第8天日间平均眼压与基线比较。

主要发现

  • 第3部分中,MGV354组第8天日间平均眼压较基线变化-0.6 mmHg,赋形剂组-1.1 mmHg,置信区间-0.7至1.7。
  • MGV354给药后最常见不良事件为结膜充血和眼充血。

关键数值与推荐

  • 第3部分患者入选标准为上午8时眼压至少24 mmHg。
  • 主要结局指标为第8天日间平均眼压较基线变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the clinical safety, tolerability, and efficacy of topically administered MGV354, a soluble guanylate cyclase (sGC) activator, in patients with ocular hypertension (OH) or glaucoma. DESIGN: Double-masked, randomized, and vehicle-controlled study. METHODS: Parts 1 and 2 evaluated safety and tolerability to identify the maximum tolerated dose (MTD) of once-daily MGV354 in 32 healthy volunteers (Part 1) and 16 patients with OH or glaucoma (Part 2) at a single clinical site. Part 3 was a multisite trial that evaluated intraocular pressure (IOP)-lowering efficacy of the MTD administered nightly for 1 week in 50 patients with minimum IOP of 24 mm Hg at 8 AM, with a main outcome measure of mean diurnal IOP at day 8 compared to baseline (ClinicalTrials.govNCT02743780). RESULTS: There was no difference in favor of MGV354 for IOP lowering; change from baseline to day 8 in mean diurnal IOP was -0.6 mm Hg for MGV354-treated patients and -1.1 mm Hg for vehicle-treated patients in Part 3, with a confidence interval of -0.7 to 1.7. The most common adverse events reported after MGV354 administration were conjunctival and ocular hyperemia. CONCLUSIONS: Overall, MGV354 0.1% demonstrated no statistically significant effect compared to vehicle in lowering IOP based on the study's main outcome measure. MGV354 produced ocular hyperemia consistent with its pharmacology.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Stacy R, Huttner K, Watts J, et al. A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma. Am J Ophthalmol. 2018. PMID: 29802818. doi:10.1016/j.ajo.2018.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。